Candel Orphan Drug Designation for CAN-3110 for Glioma

 

• FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approved
   
• CAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting

https://www.biospace.com/article/releases/fda-grants-orphan-drug-designation-for-can-3110-for-the-treatment-of-recurrent-high-grade-glioma/